Niaspan and Tooth extraction - a phase IV clinical study of FDA data

Summary:

Tooth extraction is reported as a side effect among people who take Niaspan (niacin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Pain.

The phase IV clinical study analyzes which people have Tooth extraction when taking Niaspan. It is created by eHealthMe based on reports of 44,502 people who have side effects when taking Niaspan from the FDA, and is updated regularly.

What is Niaspan?

Niaspan has active ingredients of niacin. It is often used in high blood cholesterol. eHealthMe is studying from 45,453 Niaspan users. Check the latest studies of Niaspan.

What is Tooth extraction?

Tooth extraction is found to be associated with 1,116 drugs and 856 conditions by eHealthMe. Check the latest studies of Tooth extraction.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

44,502 people reported to have side effects when taking Niaspan.
Among them, 25 people (0.06%) have Tooth extraction.

Among these 25 people:

How long have people been on Niaspan when they have Tooth extraction? *

What is the gender of people who have Tooth extraction when taking Niaspan? *

female: 52 %
male: 48 %

What is the age of people who have Tooth extraction when taking Niaspan? *

What are other drugs people take besides Niaspan? *

What are other side effects people have besides Tooth extraction? *

Pain: 16 people, 64.00%
Bone Disorder: 15 people, 60.00%
Stress And Anxiety: 14 people, 56.00%
Tooth Abscess (pus formation in tooth): 11 people, 44.00%
Osteonecrosis Of Jaw (death of bone of jaw): 11 people, 44.00%
Oedema Peripheral (superficial swelling): 11 people, 44.00%
Decreased Interest: 10 people, 40.00%
Sinusitis (inflammation of sinus): 9 people, 36.00%
Injury: 9 people, 36.00%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 9 people, 36.00%

What are the existing conditions these people have? *

Pain: 7 people, 28.00%
Breast Cancer: 6 people, 24.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 5 people, 20.00%
Osteoporosis (bones weak and more likely to break): 5 people, 20.00%
Sinus Congestion (blockage of sinus): 4 people, 16.00%
Bone Density Decreased: 4 people, 16.00%
Bone Neoplasm Malignant (cancer of bone): 4 people, 16.00%
Stress And Anxiety: 4 people, 16.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 16.00%
Metastases To Bone (cancer spreads to bone): 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Niaspan and have Tooth extraction?

- Check whether Tooth extraction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Niaspan:

Niaspan (45,453 reports)

Tooth extraction treatments and more:

Tooth extraction (20,456 reports)

Browse all side effects of Niaspan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tooth extraction:

Tooth extraction (1,116 drugs)

Browse all the conditions that are associated with Tooth extraction:

Tooth extraction (856 conditions)

Related publications that referenced our studies

Loebl T, Raskin S, "A novel case report: acute manic psychotic episode after treatment with niacin", The Journal of neuropsychiatry and clinical neurosciences, 2013 Jan .
Loebl T, Raskin S, "A novel case report: acute manic psychotic episode after treatment with niacin", The Journal of neuropsychiatry and clinical neurosciences, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on niacin (the active ingredients of Niaspan) and Niaspan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.